Filing Flows › CytomX Therapeutics (CTMX) › How it makes money
How CytomX Therapeutics (CTMX) makes money
CytomX Therapeutics (CTMX) made $1.7M of revenue in the third quarter 2026 (Q3 2026), -72% from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $1.7M | 100.0% |
| Income tax | $61K | 3.6% |
| Operating cash flow | $16.6M | 986.3% |
| Free cash flow | $16.1M | 951.4% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $1.7M | -72% |
| Q2 2026 | $1.4M | -92% |
| Q1 2026 | $10.3M | -80% |
| Q4 2025 | $663K | -98% |
| Q3 2025 | $6.0M | -82% |
| Q2 2025 | $18.7M | -26% |
| Q1 2025 | $50.9M | +23% |
From CytomX Therapeutics' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does CytomX Therapeutics make money?
CytomX Therapeutics (CTMX) made $1.7M of revenue in the third quarter 2026 (Q3 2026), -72% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.